Hybrid Immunity from Gam-COVID-Vac Vaccination and Natural SARS-CoV-2 Infection Confers Broader Neutralizing Activity against Omicron Lineage VOCs Than Revaccination or Reinfection.

Hybrid Immunity from Gam-COVID-Vac Vaccination and Natural SARS-CoV-2 Infection Confers Broader Neutralizing Activity against Omicron Lineage VOCs Than Revaccination or Reinfection.

Publication date: Jan 06, 2024

SARS-CoV-2 has a relatively high mutation rate, with the frequent emergence of new variants of concern (VOCs). Each subsequent variant is more difficult to neutralize by the sera of vaccinated individuals and convalescents. Some decrease in neutralizing activity against new SARS-CoV-2 variants has also been observed in patients vaccinated with Gam-COVID-Vac. In the present study, we analyzed the interplay between the history of a patient’s repeated exposure to SARS-CoV-2 antigens and the breadth of neutralization activity. Our study includes four cohorts of patients: Gam-COVID-Vac booster vaccinated individuals (revaccinated, RV), twice-infected unvaccinated individuals (reinfected, RI), breakthrough infected (BI), and vaccinated convalescents (VC). We assessed S-protein-specific antibody levels and the ability of sera to neutralize lentiviral particles pseudotyped with Spike protein from the original Wuhan variant, as well as the Omicron variants BA. 1 and BA. 4/5. Individuals with hybrid immunity (BI and VC cohorts) exhibited significantly higher levels of virus-binding IgG and enhanced breadth of virus-neutralizing activity compared to individuals from either the revaccination or reinfection (RV and RI) cohorts. These findings suggest that a combination of infection and vaccination, regardless of the sequence, results in significantly higher levels of S-protein-specific IgG antibodies and the enhanced neutralization of SARS-CoV-2 variants, thereby underscoring the importance of hybrid immunity in the context of emerging viral variants.

Open Access PDF

Concepts Keywords
Basel antibody
Covid COVID-19
Mutation hybrid immunity
Vaccinated neutralization breadth
Viral variants of concern
virus escape

Semantics

Type Source Name
disease VO vaccination
disease MESH SARS-CoV-2 Infection
pathway REACTOME SARS-CoV-2 Infection
disease MESH Reinfection
disease MESH mutation rate
disease VO vaccinated
disease IDO history
disease VO unvaccinated
disease MESH infection
drug DRUGBANK Diflunisal
drug DRUGBANK Rasagiline
drug DRUGBANK Coenzyme M
disease VO vaccine
disease IDO replication
disease IDO blood
disease VO USA
drug DRUGBANK Benzylpenicillin
drug DRUGBANK Streptomycin
disease VO Glycoprotein
drug DRUGBANK Ethanol
drug DRUGBANK Water
disease IDO production
disease IDO assay
drug DRUGBANK Methylergometrine
disease VO volume
disease VO company
disease VO dose
disease VO Sputnik V
disease MESH secondary infections
drug DRUGBANK Nevirapine
disease IDO secondary infection
disease VO titer

Original Article

(Visited 1 times, 1 visits today)